Cardiogenic shock: The role of inflammation

Acute Cardiac Care

Volumn 12, Issue 4, 2010, Pages 115-118

  Shpektor, Alexander ^a  

^a A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BIOLOGICAL MARKER; BRADYKININ; C REACTIVE PROTEIN; CORTICOSTEROID; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEXELIZUMAB; PHOSPHOLIPASE A; PROCALCITONIN; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; CARDIOGENIC SHOCK; CLINICAL TRIAL; COMPLEMENT SYSTEM; DRUG MEGADOSE; ENZYME INHIBITION; HEART INFARCTION; HEMOFILTRATION; HUMAN; INFLAMMATION; LOW DRUG DOSE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; STEROID THERAPY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

ADRENAL CORTEX HORMONES; CYTOKINES; ENZYME INHIBITORS; HEMOFILTRATION; HUMANS; MYOCARDIAL INFARCTION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, CARDIOGENIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 78049508801     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.3109/17482941.2010.523705     Document Type: Review

References (34)

1. Lim N, Dubois M-J, De Backer D, Vincent J-L. Do all nonsurvivors of cardiogenic shock die with a low cardiac index? Chest 2003;124:1885-91.
2. Hochman J. Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation 2003;107:2998-3002.
3. Kohsaka S, Menon V, Iwata K, Lowe A, Sleeper LA, Hochman JS; SHOCK INVESTIGATORS. Microbiological profile of sepsis complication in patients with cardiogenic shock following acute myocardial infarction (from the Shock Study). Am J Cardiol. 2007;99:802-4.
4. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588-95.
5. Parillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W, et al. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest. 1985;76:1539-53.
6. Kumar A, Wood K, Parillo JE. Circulating substances and energy metabolism in septic shock. Crit Care Med. 2003;31:632-3.
7. Cain BS, Meldrum DR, Dinarello CA, et al. Tumor necrosis factor α and interleukin-1 β synergistically depress human myocardial function. Crit Care Med. 1999;27:1309-18.
8. Joulin O, Petillot P, Laballete M, Lancel S, Neveie HR, et al. Cytokine profile of human septic shock serum inducing cardiomyocyte contractile dysfunction. Physiol Res. 2007;56:291-7.
9. Pudil R, Krejsek J, Pidrman V, Gregor J, Tichy M, Bures J, et al. Inflammatory response to acute myocardial infarction complicated by cardiogenic shock. Acta Medica 2001;44:149-51.
10. Brunkhorst FM. Clark AL, Forycki ZF, Anker SD. Pyrexia, procalcitonine, immune activation and survival in cardiogenic shock: The potential importance of bacterial translocation. Int. J. Cardiol. 1999;72:3-10.
11. Theroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, et al. Prognostic significance of blood markers of inflammation in patients with ST-elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: A substudy of the COMMA trial. Eur Heart J. 2005:26; 1964-70.
12. Geppert A, Dorninger A, Delle-Karth G, Zorn G, Heinz G, Huber K, et al. Plasma concentrations of interlukin-6, organ failure, vasopressor support, and successful revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2006;34:2035-42.
13. Domingues-Rodrigues A, Samimi-Fard S, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am J Cardiol. 2008;101:1537-40.
14. Flesch M, Kilter H, Cremers B, Lenz O, Sudkamp M, Kuhn-Regnier Bohm M, et al. Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J Pharmacol Exp Ther. 1997;281:1340-9.
15. Mohan P, Brutsaert DL, Paulus WJ, Sys SU. Myocardial contractile response to nitric oxide and cGMP. Circulation 1996;93:1223-9.
16. Umans JG, Levi R. Nitric oxide in regulation of blood flow and arterial pressure. Annu Rev Physiol. 1995;57:771-90.
17. Lima B, Forrester M, Hess D, Stamler J. S-nitrosylation in cardiovascular signaling Circ Res. 2010;106:633-46.
18. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109-42.
19. Forstermann U, Closs EI, Pollock JS, Nakane M, Sehwarr P, Cath I, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning and functions. Hypertension 1994;23:1121-31.
20. Ferdinandy P, Danial H, Ambrul J, et al. Peroxynitrate is a major contributor to cytokine-induced myocardial contractile failure. Circ Res. 2000;87:241-7.
21. Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res. 1994;31:131-43.
22. Sanchez de Miguel L, Arriero MM, Jimenez P, Garcia-Mendez A, de Frutos T, Jimener A, et al. Nitric oxide production by neutrophils obtained from patients during acute coronary syndromes: Expression of the nitric oxide syntase isoforms. JACC 2002;39:818-25.
23. Feng Q, Lu X, Jones D L, Shen J, Arnold JM. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 2001;104:70.
24. Cotter G, Kaluski E, Blatt A, Milovanov O, Moshkovitz Y, Zaindenstein R, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000;101:1358.
25. Cotter G, Kaluski E, Milo O, Blatt A, Salah A, Hendler A, et al. LINKS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock. Eur Heart J. 2003;24:1287-95.
26. Dzavik V, Cotter G, Reynolds HR, Alexander JH, Ramanathan K, Stebbins AL, et al. Effect of nitric oxide synthase inhibiyion on haemodynamcs and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: A phase II dose-ranging study. Eur Heart J. 2007;28:1109-16.
27. The TRIUMPH investigators. effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: The TRIUMPH randomized controlled trial. JAMA 2007;297:1657-66.
28. Nordhaug D, Seensrud T, Aghajani E, Korvald C, Myrmel T. Nitric oxide synthase inhibition improves myocardial efficiency and ventriculo-arterial matching in acute ischemic heart failure. Eur heart Fail. 2004;6:705-13.
29. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, et al. Multiple-center, randomized, placebocontrolled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med. 2004;32:21-30.
30. Granger CB, Mahaffey KW, Weaver WD, Therou XP, Hochman JS, Filloon TG, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction. COMMA Trial. Circulation 2003;108:1184-90.
31. The APEX AMI investigators. Pexelizumab for acute S T-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention. JAMA 2007;297:43-51.
32. Seam N, Suffredini AF. Mechanisms of sepsis and insights from clinical trials. Drug Discov Today Dis Mech. 2007;4:83-93.
33. Annane D, Bellisant E, Bollart P-E. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009;301:2362-75.
34. Bouman C, Oudemans-van Straten HM, Schultz MJ, Vroom MB. Hemofiltration in sepsis and systemic inflammatory response: the role of dosing and timing. J Crit Care 2007;22:1-12.